Cytek Biosciences/$CTKB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Ticker
$CTKB
Sector
Primary listing
Employees
688
Headquarters
Website
CTKB Metrics
BasicAdvanced
$525M
-
-$0.05
1.34
-
Price and volume
Market cap
$525M
Beta
1.34
52-week high
$7.30
52-week low
$2.37
Average daily volume
1.1M
Financial strength
Current ratio
5.225
Quick ratio
4.35
Long term debt to equity
3.949
Total debt to equity
6.272
Interest coverage (TTM)
-226.62%
Profitability
EBITDA (TTM)
-21.991
Gross margin (TTM)
54.42%
Net profit margin (TTM)
-3.27%
Operating margin (TTM)
-15.03%
Effective tax rate (TTM)
15.34%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-3.77%
Return on equity (TTM)
-1.67%
Valuation
Price to revenue (TTM)
2.714
Price to book
1.39
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
49.3
Free cash flow yield (TTM)
2.03%
Free cash flow per share (TTM)
0.084
Growth
Revenue change (TTM)
-0.85%
Earnings per share change (TTM)
-64.02%
3-year revenue growth (CAGR)
9.70%
3-year earnings per share growth (CAGR)
34.20%
What the Analysts think about CTKB
Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.
Bulls say / Bears say
Cytek reported adjusted EPS of $0.07 for the quarter ended December 2024, surpassing the Zacks Consensus estimate of $0.06, demonstrating earnings resilience. (Nasdaq)
In Q2 2025, total recurring revenue grew 16% year-over-year and now represents 32% of trailing 12-month revenue, underscoring the strength of its high-margin service and reagent business. (Cytek Biosciences IR)
Cytek launched its next-generation Aurora Evo full-spectrum flow cytometer in Q2 2025, expanding its product lineup and enhancing competitive positioning. (Cytek Biosciences IR)
Total revenue for Q2 2025 declined 2% year-over-year to $45.6 million, reflecting soft instrument sales in a challenging macro environment. (Cytek Biosciences IR)
The company narrowed its full-year 2025 revenue guidance to a ‑2% to +2% range, signaling management’s cautious outlook for near-term growth. (Cytek Biosciences IR)
Cytek’s reported Q4 2024 revenue of $57.48 million missed the Zacks Consensus estimate by 9.5%, suggesting potential demand headwinds in its core markets. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
CTKB Financial Performance
Revenues and expenses
CTKB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytek Biosciences stock?
Cytek Biosciences (CTKB) has a market cap of $525M as of September 13, 2025.
What is the P/E ratio for Cytek Biosciences stock?
The price to earnings (P/E) ratio for Cytek Biosciences (CTKB) stock is 0 as of September 13, 2025.
Does Cytek Biosciences stock pay dividends?
No, Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Cytek Biosciences dividend payment date?
Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytek Biosciences?
Cytek Biosciences (CTKB) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.